Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer (PFE) Tests COVID-19 Booster & Pneumococcal Vaccine Combo

Pfizer's (PFE) study is testing its pneumococcal vaccine candidate along with COVID-19 booster shot on 600 fully vaccinated adults 60 years and older.

AstraZeneca's (AZN) Coronavirus Vaccine Gets EUA in Japan

AstraZeneca's (AZN) COVID-19 vaccine Vaxzevria gets an approval for emergency use in Japan for active immunization of individuals aged 18 years and older.

The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck

The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck

Pfizer/BioNTech to Supply 1.8B More Doses of Comirnaty in EU

Pfizer (PFE)/BioNTech (BNTX) have a total supply order for 2.4 billion doses of its COVID-19 vaccine, Comirnaty in Europe.

Merck's (MRK) Pneumococcal Vaccine Succeeds in Pediatric Trials

Merck's (MRK) 15-valent pneumococcal conjugate vaccine candidate, V114, demonstrates comparable immunogenicity and safety compared to a lower valency vaccine in infants and children.

Kinjel Shah headshot

Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal

Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints

Sarepta (SRPT) Rises on Robust DMD Gene Therapy Study Data

Sarepta's (SRPT) lead gene therapy candidate, SRP-9001, demonstrates robust improvement in expression of micro-dystrophin protein in DMD patients after 12 weeks of treatment.

Corcept's (CORT) Lead Drug Korlym Aids Growth Amid Competition

Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, sole dependence on Korlym for growth remains an overhang.

Mark Vickery headshot

Top Stock Reports for Mastercard, Home Depot & Walt Disney

Today's Research Daily features new research reports on 12 major stocks, including Mastercard Incorporated (MA), The Home Depot, Inc. (HD), and The Walt Disney Company (DIS).

Pfizer (PFE) COVID-19 Vaccine for Adolescents Endorsed by CDC

Pfizer (PFE)/BioNTech (BNTX) vaccine was 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.

Sweta Jaiswal, FRM headshot

Biotech ETFs to Suffer as US Backs IP Waiver for COVID-19 Vaccines

The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.

Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat

Exelixis (EXEL) missed on earnings in the first quarter but beats on revenues.

PFE vs. NVO: Which Stock Should Value Investors Buy Now?

PFE vs. NVO: Which Stock Is the Better Value Option?

Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y

Corcept (CORT) reports wider-than-expected loss in the first quarter of 2021, with its revenues also missing estimates.

Stock Market News for May 7, 2021

Wall Street closed sharply higher on Thursday following strong labor market Data.

Aerie's (AERI) Q1 Loss Wider Than Expected, Revenues Miss

Aerie (AERI) incurs a wider loss in the first quarter of 2021 and sales miss expectations.

Deciphera (DCPH) Q1 Loss Narrower Than Expected, Revenues Beat

Deciphera (DCPH) posts a narrower loss in the first quarter while sales beat on the encouraging uptake of Qinlock.

Has Pfizer (PFE) Outpaced Other Medical Stocks This Year?

Is (PFE) Outperforming Other Medical Stocks This Year?

Pfizer (PFE) Gains As Market Dips: What You Should Know

Pfizer (PFE) closed at $39.95 in the latest trading session, marking a +0.3% move from the prior day.

Pfizer (PFE) Q1 Earnings Beat, COVID-19 Vaccine Boosts Sales

Pfizer (PFE) beats estimates for earnings and sales in the first quarter. It lifts its financial outlook for 2021. Stock up.

Q1 Earnings Season Maintains its Momentum

Q1 Earnings Season Maintains its Momentum.

Mark Vickery headshot

Pfizer, UnderArmour Beat; Trade Deficit at All-Time Low

A sense of caution has begun to permeate the market off near-all-time highs in the indexes, and Pfizer looks to be a recipient of this today.

Pfizer (PFE) Q1 Earnings and Revenues Surpass Estimates

Pfizer (PFE) delivered earnings and revenue surprises of 17.72% and 8.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Pfizer's (PFE) Key Drugs Likely to Drive Its Q1 Earnings

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.